Posters

      Selection of biomarkers of exposure for a population study of U.S. adult smokers to cigarette smoke

      Kinser, R. D.; Carchman, R. A.; Leyden, D. E.; Sanders, E. B.; Stabbert, R.; Tricker, A. R.; von Holt, K.; R-Walk, R-A. Walk.

      Conference date
      Jul 8, 2001
      Conference name
      IXTH International Congress of Toxicology (ICT)
      Link to more information
      Topic
      Summary

      In our paradigm for the evaluation of harm reduction by new cigarette designs, measurements of exposure to both the gas/vapor phase and particulate phase ('tar') of mainstream cigarette smoke are required. We have identified biomarkers based on known mainstream cigarette smoke chemistry and the need to investigate toxicologically relevant smoke constituents. Selected biomarkers of gas/vapor phase smoke exposure are CO in exhaled breath, blood COHb, and acetonitrile in both exhaled breath and blood. Relevant biomarkers of particulate phase smoke exposure are hemoglobin adducts of the aromatic amines 3- and 4-aminobiphenyl, 24 h excretion of two urinary metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and the sum total of six urinary metabolites of nicotine. A justification for the smoke constituents chosen for study, the criteria used to select the above biomarkers of cigarette smoke exposure, and the pilot study planned to evaluate these choices will be presented. 

      Related Publications

      Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

      Clinical

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.